RecruitingNCT02402244
Project: Every Child for Younger Patients With Cancer
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Sponsor
Children's Oncology Group
Enrollment
75,000 participants
Start Date
Nov 3, 2015
Study Type
OBSERVATIONAL
Conditions
Malignant Solid NeoplasmNeuroendocrine NeoplasmCentral Nervous System NeoplasmMalignant NeoplasmAdrenal Gland PheochromocytomaCarcinoma In SituChildhood Immature TeratomaChildhood Kidney NeoplasmChildhood Langerhans Cell HistiocytosisChildhood Mature TeratomaCongenital Mesoblastic NephromaDesmoid FibromatosisGanglioneuromaLymphoproliferative DisorderMelanocytic NeoplasmMyeloproliferative NeoplasmNeoplasm of Uncertain Malignant PotentialStromal Neoplasm
Summary
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Eligibility
Max Age: 25 Years
Inclusion Criteria20
- Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem
- Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority
- Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:
- All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one "1" (borderline), two "2" (carcinoma in situ) or three "3" (malignant)
- All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant
- All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant
- The following other benign/borderline conditions:
- Mesoblastic nephroma
- Teratomas (mature and immature types)
- Myeloproliferative diseases including transient myeloproliferative disease
- Langerhans cell histiocytosis
- Lymphoproliferative diseases
- Desmoid tumors
- Gonadal stromal cell tumors
- Neuroendocrine tumors including pheochromocytoma
- Melanocytic tumors, except clearly benign nevi
- Ganglioneuromas
- Subjects must be =\< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network \[NCTN\]) therapeutic study, for which there is a higher upper age limit
- All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission
- If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1
Interventions
OTHERCytology Specimen Collection Procedure
Undergo cytology specimen collection
OTHERMedical Chart Review
Undergo medical data review
Locations(278)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02402244
Related Trials
National Cancer Institute "Cancer Moonshot Biobank"
NCT04314401152 locations
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT0699589836 locations
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
NCT0725273913 locations
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
NCT038192961 location
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
NCT062020661 location